Search

Displaying results 5041 - 5050 of 10000 in total
  1. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: VITRAKVI®CÁPSULAS DE 100MG
  2. Drug

    Cefamandole nafate

    go.drugbank.com/drugs/DB14725
    ApprovedWithdrawn

    Synonyms: O-formylcefamandoleCategories: Heterocyclic Compounds, 2-Ring
  3. Drug

    Ceftobiprole medocaril

    go.drugbank.com/drugs/DB14733
    Approved

    Ceftobiprole medocaril is a prodrug of [ceftobiprole], a fifth-generation semisynthetic cephalosporin antibacterial. … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European

    Categories: Heterocyclic Compounds, 2-RingProducts: ZEVTERA® POLVO LIOFILIZADO
  4. Drug

    Solriamfetol

    go.drugbank.com/drugs/DB14754
    ApprovedInvestigational

    Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated

    Synonyms: (2R)-2-amino-3-phenylpropyl carbamateCategories: MATE 1 Inhibitors, MATE 1 Substrates
  5. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.

  6. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring
  7. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516] … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor

    Synonyms: 奥赛利定Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  8. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    Imetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase. … cell morphology and a risk for transformation to acute myeloid leukemia.

  9. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).

    Synonyms: 6-(((1S)-1-Phenylethyl)amino)-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dioneCategories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  10. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow … Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation.